EP0984901B1 - Hydroxylapatite gel - Google Patents
Hydroxylapatite gel Download PDFInfo
- Publication number
- EP0984901B1 EP0984901B1 EP98934899A EP98934899A EP0984901B1 EP 0984901 B1 EP0984901 B1 EP 0984901B1 EP 98934899 A EP98934899 A EP 98934899A EP 98934899 A EP98934899 A EP 98934899A EP 0984901 B1 EP0984901 B1 EP 0984901B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydroxylapatite
- moldable
- composition
- gel
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 title claims abstract description 100
- 229910052588 hydroxylapatite Inorganic materials 0.000 title claims abstract description 99
- 239000000463 material Substances 0.000 claims abstract description 32
- 239000007943 implant Substances 0.000 claims abstract description 31
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 25
- 229910052751 metal Inorganic materials 0.000 claims abstract description 23
- 239000002184 metal Substances 0.000 claims abstract description 23
- 238000000576 coating method Methods 0.000 claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 238000010335 hydrothermal treatment Methods 0.000 claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 239000011575 calcium Substances 0.000 claims abstract description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 10
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract description 9
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 7
- 238000001356 surgical procedure Methods 0.000 claims abstract description 6
- 238000003980 solgel method Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 14
- 239000000316 bone substitute Substances 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 11
- 238000000465 moulding Methods 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 9
- 238000007669 thermal treatment Methods 0.000 claims description 9
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 9
- 241000195493 Cryptophyta Species 0.000 claims description 7
- 239000001506 calcium phosphate Substances 0.000 claims description 7
- -1 Mg2+ ions Chemical class 0.000 claims description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 6
- 239000008151 electrolyte solution Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000010936 titanium Substances 0.000 claims description 6
- 229910052719 titanium Inorganic materials 0.000 claims description 6
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 6
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 6
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 4
- 230000000921 morphogenic effect Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 3
- 239000012876 carrier material Substances 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 2
- 229910000388 diammonium phosphate Inorganic materials 0.000 claims description 2
- 235000019838 diammonium phosphate Nutrition 0.000 claims description 2
- PEYVWSJAZONVQK-UHFFFAOYSA-N hydroperoxy(oxo)borane Chemical compound OOB=O PEYVWSJAZONVQK-UHFFFAOYSA-N 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 230000006835 compression Effects 0.000 claims 2
- 238000007906 compression Methods 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000011230 binding agent Substances 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 3
- 229960002218 sodium chlorite Drugs 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- WGKMWBIFNQLOKM-UHFFFAOYSA-N [O].[Cl] Chemical compound [O].[Cl] WGKMWBIFNQLOKM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910001919 chlorite Inorganic materials 0.000 description 2
- 229910052619 chlorite group Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241001474374 Blennius Species 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical class [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- ICSSIKVYVJQJND-UHFFFAOYSA-N calcium nitrate tetrahydrate Chemical compound O.O.O.O.[Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ICSSIKVYVJQJND-UHFFFAOYSA-N 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
- C04B35/447—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on phosphates, e.g. hydroxyapatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/32—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B25/00—Phosphorus; Compounds thereof
- C01B25/16—Oxyacids of phosphorus; Salts thereof
- C01B25/26—Phosphates
- C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
- C01B25/325—Preparation by double decomposition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/00592—Coating or prosthesis-covering structure made of ceramics or of ceramic-like compounds
- A61F2310/00796—Coating or prosthesis-covering structure made of a phosphorus-containing compound, e.g. hydroxy(l)apatite
Definitions
- the invention relates to a mouldable hydroxyapatite mass containing it Moldings and their use, in particular in the field of bone surgery.
- the bone implant should have a structure that corresponds to the the bone is as similar as possible. It is also high mechanical Stability desirable.
- the implant material should also as a carrier for active ingredients such as growth-promoting or -inhibiting substances.
- a hydroxyapatite material which is obtained from the calcium carbonate skeleton of lime-encrusting algae, has proven itself as bone substitute material. Such a material is described in DE 37 09 897 C2.
- the granular hydroxyapatite material obtained by hydrothermal synthesis is shaken into a molded article with slaked lime as a binder and then subjected to a hydrothermal treatment again.
- the bone implant thus obtained has a high interconnectivity and a high specific surface area. In its chemistry and crystalline structure, it is much more similar to bones than other bone replacement materials. In some special applications, however, bone replacement materials are required that have an even higher porosity and particularly high mechanical stability.
- the object of the invention is to provide materials which are suitable for producing a bone substitute material which, in its chemistry and crystalline structure, is as similar as possible to natural bones, has a very porous microstructure, but has high mechanical stability.
- the materials should be easy to manufacture, inexpensive and easy to process. In addition, they should allow the crystal phase portion and the strength of the bone substitute material to be specifically adjusted during processing.
- the invention further relates to the use of the hydroxyapatite molded body according to claim 16.
- the hydroxyapatite molded body is also present as a coating in a metal implant according to claim 19.
- the invention relates to a method for producing the metal implant according to claim 20, and to a method for producing the hydroxyapatite shaped body according to claim 22. Further procedural variants and forms of training result from the subclaims.
- the invention relates to a moldable hydroxyapatite mass, which is obtainable by a sol-gel process.
- a sol-gel process there becomes an alkaline aqueous solution of a calcium salt with an alkaline aqueous solution of a phosphate salt implemented a sol.
- the stoichiometry is included chosen such that the ratio of calcium to phosphorus Ratio in the hydroxyapatite corresponds.
- the molar ratio from calcium to phosphorus in sol production is therefore in the Range of approximately 1.67. Then the sol obtained in this way converted to a gel by hydrothermal treatment.
- the pH in sol production is preferably one Range from 9 to 12 and particularly useful between 10.5 and 11.
- the desired pH range can be added by adding the usual Bases can be adjusted. Ammonia is particularly suitable for this. It also turned out to be advantageous, initially separate both aqueous solutions to the desired one Adjust the pH value and adjust the pH value if necessary mixing both solutions again in the desired range bring to.
- the sol is advantageously produced in a temperature range between 10 ° and 40 ° C, particularly useful at Room temperature (20 ° to 25 ° C).
- 0.1 to 1N aqueous solutions of the calcium salt or the phosphate salt can be used in the preparation of the sol.
- 0.3 to 0.5N aqueous solutions of the salts are particularly suitable. All soluble calcium and phosphate salts that should not contain any body-incompatible constituents can be used as starting materials.
- a suitable calcium salt is, for example, calcium nitrate. Diammonium hydrogen phosphate can be used as the phosphate salt.
- the sol forms after the Mix the two aqueous solutions by standing for a period of several days.
- the sol is then converted to a gel by hydrothermal treatment.
- the hydrothermal treatment is advantageously carried out in a temperature range of 180 to 200 ° C. Particularly advantageous it is carried out in an autoclave.
- An autoclave Are suitable especially with polytetrafluoroethylene or similar inert Linings coated autoclaves. It is an advantage that Fill autoclaves to a maximum of two thirds and the hydrothermal Treatment under the then occurring saturation vapor pressure the solution.
- the pH at Conversion to the gel is advantageously in the same range as in sol production, i.e. between 9 and 12 and in particular between 10.5 and 11.
- the hydrothermal treatment During the hydrothermal treatment, crystal nuclei form in sol and fine crystals of hydroxyapatite. Depending on The duration of the hydrothermal treatment of the sol can be the crystal phase portions Controlled in the hydroxyapatite gel become. This way the physical properties of the hydroxyapatite gel can be influenced in a targeted manner.
- the hydrothermal treatment continues until the proportion of Crystal nuclei and fine crystalline hydroxyapatite in the gel 80% and in particular about 90%. Remain in the gel mass preserve up to two thirds of the water contained in the sol.
- the gel according to the invention usually contains after its Production up to 70 wt .-% water. A medium water content is about 60% by weight. If you leave the hydroxyapatite gel longer Standing for a while, the gel settles and it forms aqueous supernatant. By pouring off this supernatant if desired, reduce the water content of the gel in a targeted manner.
- This malleable Hydroxyapatite composition according to claim 1, comprising in addition to the above-described hydroxylapatite gel, which acts as a binder, a calcium-containing granular filler.
- Suitable as fillers are, for example, all those in the field of bone surgery are already in use.
- Particularly suitable as granular filler are hydroxyapatite materials which can be obtained from lime-encrusting algae. Examples are described in German Patent 37 09 897. In those described there The calcium carbonate skeleton remains the materials Preserve algae so that the material has a high interconnectivity Porosity and has a large specific surface.
- a modified, tricalcium phosphate-containing hydroxylapatite material can also be used as the granular filler for the moldable hydroxylapatite mass, which is obtainable by converting an algae hard tissue freed from organic compounds into an alkaline aqueous phosphate solution with the addition of Mg 2+ - Ions at elevated temperature.
- This tricalcium phosphate-containing hydroxyapatite material advantageously has a tricalcium phosphate content of 20 to 90% by weight.
- the hard algae tissue as in the case of the unmodified hydroxyapatite materials, is expediently obtained from calcareous seaweed, in particular from those of the species Corallinacea or Codiacea.
- the invention Hydroxyapatite gel and the granular solid in one wide proportions can be mixed. Suitable are, for example, weight ratios of hydroxyapatite gel and granular solid between 10: 1 and 1:10, here of a hydroxyapatite gel with a water content of about 60 % By weight is assumed.
- the respective shares will be accordingly the desired later use of the invention malleable hydroxyapatite mass selected.
- the way on which the malleable mass is to be processed plays a role in the selection of the proportions of the two components. When using the moldable hydroxyapatite composition according to the invention higher proportions of gel can be used for a coating make processing easier.
- bone replacement materials which have a high mechanical strength - are usually contain a higher proportion of granular solid.
- weight ratios of Gel to solid between 1: 5 and 1: 8 can be used.
- the moldable hydroxylapatite composition according to the invention can be further Contain components such as those found in bone substitute materials or filter materials are common.
- the Add mass at least one active ingredient.
- examples are growth promoting or inhibiting substances.
- Specific examples are antibiotics, chemotherapy drugs, anti-tumor compounds and bone inductive substances.
- Exemplary for the latter can be bone morphogenic proteins (bone morphogenic proteins).
- These active ingredients can be used in the invention Be incorporated, or they will be on the finished moldings produced from the composition according to the invention applied. The appropriate for each active ingredient clinically active amount used.
- the moldable hydroxyapatite composition according to the invention is through any proportion of hydroxyapatite gel malleable. This considerably simplifies the manufacture, even in a complicated manner assembled molded body. If as a granular filler a hydroxyapatite material obtained from limestone encrusting algae a malleable mass is obtained which consists almost exclusively of hydroxyapatite. From this mass of molded articles are not only extraordinary body-friendly, but they also have one exceptionally porous microstructure with high mechanical Stability. The hydroxyapatite mass according to the invention is therefore extremely good for the production of bone replacement materials suitable. In addition, the physical Properties of the malleable mass and as a result also specifically influence the molded body produced from it.
- the crystallinity can continue about the type and duration of the thermal treatment of the malleable hydroxyapatite mass are affected with the a solid molded body is produced.
- the moldable hydroxyapatite composition according to the invention filled into a suitable form and before curing first degassed appropriately.
- this is suitable treatment by ultrasound.
- the malleable mass as mentioned, be compressed.
- the thermal treatment for The mass is expediently cured in a temperature range between 500 ° and 650 ° C, especially between 550 ° and 600 ° C.
- the duration of the thermal treatment depends on the composition of the moldable mass and the size of the molded body. Usually the time of treatment is between about half an hour and several hours.
- the molded body according to the invention produced reworked with usual surgical tools and into its final Be brought into shape.
- coatings such as those from bone-inductive compounds, which have already been mentioned were, on the shaped hydroxyapatite body according to the invention be applied.
- the shaped hydroxyapatite body according to the invention is suitable excellent for use in the field of bone surgery, in particular as a bone replacement material or as a carrier material for active substances. Because of their porous structure can however, the moldings according to the invention also as filter materials be used.
- the hydroxyapatite moldings according to the invention are suitable also as a bioactive coating on metal implants and especially on titanium bone implants.
- the invention relates in a further aspect, such a metal implant, which is a coating of the molded hydroxyapatite according to the invention includes.
- a metal implant which is a coating of the molded hydroxyapatite according to the invention includes.
- To manufacture the implant on the metal surface a layer of the invention malleable hydroxyapatite mass applied and this one subjected to thermal treatment between 500 ° and 650 ° C, such as this has been described above.
- thermal treatment between 500 ° and 650 ° C, such as this has been described above.
- To the adhesion of the coating to improve on the metal surface this surface appropriately treated before their coating.
- Treatments to improve adhesion are for metal implants known.
- These known surface treatment methods can also applied before applying the coating according to the invention become. However, treatment is preferably carried out which is also the subject of this invention.
- the surface of the metal is oxidized before application of the coating in an electrolytic solution with spark discharge at a temperature between -10 and -20 ° C. until the thickness of the oxide layer is between 25 and 40 ⁇ m.
- the oxidation takes place at an alternating current of 50 Hz at a voltage between 110 and 200 V.
- the aqueous electrolyte solution used comprises: Polyethylene glycol (molecular weight 200 to 400) 80 to 200 ml / l At least one chlorine-oxygen acid or its salt 5 to 20 g / l such as Amin 10 to 30 ml / l and or Hydrofluoric acid or its salts 2 to 25 g / l and or Phosphoric acid or its salts 20 to 80 g / l and or Perboric acid or its salts 10 to 40 g / l
- the alkali metal salts of chlorine oxygen acids are preferably used as the oxidizing agent, in particular the chlorates and chlorites such as sodium chlorate or sodium chlorite. Mixtures of different salts can also be used. Of the other acids, the alkali or ammonium salts are preferably used. Examples of preferred compounds are sodium fluoride, ammonium fluoride, potassium dihydrogen phosphate and sodium perborate. Aliphatic amines or alcohol amines are advantageously used as the amine, preferably triethylamine or triethanolamine.
- the oxide layer obtained according to the inventive method is then recrystallized in a firing process. expedient the oxide layer after drying for 20 to 40 minutes exposed to a temperature of 550 to 650 ° C. Advantageous are those that may still be on the oxide layer unbound ions removed with distilled water before the Mouldable composition according to the invention on the treated metal surface is applied.
- the layer thickness is expediently 5 up to 10 ⁇ m.
- the moldable mass is thermally treated as described above.
- a 0.5N aqueous solution of Ca (NO 3 ) 2 .4H 2 O and a 0.3N aqueous solution of (NH 4 ) 2 HPO 4 are adjusted separately to a pH of 10.5 with ammonia. Both solutions are mixed thoroughly in a 1: 1 ratio with stirring. If necessary, the pH of the solution thus obtained is brought to 10.5 again with ammonia. The reaction mixture is left to stand at a temperature between 20 ° and 25 ° C for five to six days. During this time, a primary apatite sol forms.
- the sol becomes hydrothermal at 180 to 200 ° C treated.
- the gel is placed in a PTFE lined autoclave, the maximum of two thirds is filled.
- the hydrothermal treatment takes place under the saturated vapor pressure of the solution.
- Treatment continues continued until at least 80% crystal nuclei and fine crystalline Have formed hydroxyapatite.
- Preferably continue hydrothermal treatment until about 90% Crystal nuclei and fine crystalline hydroxyapatite have formed.
- the hydrothermal treatment usually requires at least 24 hours. After about 30 hours of reaction time no significant change in crystallinity was observed.
- the hydroxyapatite gel obtained has a water content of about 60% by weight.
- the hydroxyapatite gel obtained is treated with a according to German patent 37 09 897 made from red algae encrusted with lime Granular hydroxyapatite material produced in one Weight ratio of 1:10 mixed. It will be a homogeneous one get pasty mass.
- the resulting hydroxyapatite mass is in a Mold filled. It is done by ultrasound radiation vented and at a pressure of 0.9 MPa for a few minutes compacted. Then the compacted mass in the Press mold in an oven at 550 to 600 ° C for about 60 minutes thermally treated. In this way, a molded body with a very porous microstructure and high mechanical strength receive. It can be reworked mechanically.
- a titanium bone implant is oxidized with spark discharge in an electrolytic solution at -10 ° C.
- the solution contains: Polyethylene glycol (MG 200) 100 ml / l Sodium chlorate / chlorite 5 g / l sodium fluoride 21 g / l potassium 68 g / l triethylamine 10 ml / l
- the oxidation is carried out at a voltage of 160 V for 5 minutes carried out. Then the treated implant comes out of solution removed, and the oxide layer produced is at 600 ° C in one Oven recrystallized for twenty minutes. Then will rinsed several times with boiling distilled water until all unbound ions are completely removed from the implant.
- the surface of the titanium bone implant is oxidized with spark discharge in an electrolytic solution at -15 ° C.
- the solution consists of: Polyethylene glycol (MG 400) 150 ml / l Sodium chlorate / chlorite 10 g / l sodium fluoride 21 g / l potassium 68 g / l sodium 38 g / l ammonium fluoride 6 g / l triethanolamine 15 ml / l
- the metal implant treated according to item 1 or 2 is included provided a coating that consists of a Hydroxyapatite gel as described above and one according to German Patent 37 09 897 produced hydroxyapatite granules in a volume ratio of 2: 0.75.
- the layer thickness is about 7 ⁇ m. After drying, the layer is at 550 ° C fixed in an oven for 40 minutes.
- the procedure is as described under point 3, but the the ratio of hydroxyapatite gel to granules 2: 1.
- the layer is fixed at 500 ° C. for 30 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
- Dental Prosthetics (AREA)
Abstract
Description
Die Erfindung betrifft eine formbare Hydroxylapatit-Masse, dieses enthaltende Formkörper sowie deren Verwendung, insbesondere im Bereich der Knochenchirurgie.The invention relates to a mouldable hydroxyapatite mass containing it Moldings and their use, in particular in the field of bone surgery.
Im Bereich der Knochenchirurgie besteht ein Bedarf an Knochenersatzstoffen und Implantaten, welche körperverträglich und gut zu bearbeiten sind. Um das Anwachsen im Körper zu erleichtern, sollte das Knochenimplantat eine Struktur aufweisen, die dem der Knochen möglichst ähnlich ist. Außerdem ist eine hohe mechanische Stabilität wünschenswert. Das Implantatmaterial sollte zudem als Träger für Wirkstoffe wie beispielsweise wachstumsfördernde oder -hemmende Substanzen geeignet sein.There is a need for bone substitutes in the field of bone surgery and implants, which are well tolerated by the body are to be processed. In order to facilitate the growth in the body, the bone implant should have a structure that corresponds to the the bone is as similar as possible. It is also high mechanical Stability desirable. The implant material should also as a carrier for active ingredients such as growth-promoting or -inhibiting substances.
Als Knochenersatzmaterial hat sich ein Hydroxylapatit-Material
bewährt, welches aus dem Calciumcarbonat-Skelett von kalkinkrustierenden
Algen gewonnen wird. Ein derartiges Material ist in
der DE 37 09 897 C2 beschrieben. Zur Herstellung von Formkörpern
wird das durch hydrothermale Synthese erhaltene granuläre
Hydroxylapatit-Material mit gelöschtem Kalk als Bindemittel in
einen Formkörper eingerüttelt und danach nochmals einer hydrothermalen
Behandlung unterzogen. Das so erhaltene Knochenimplantat
besitzt eine hohe interkonnektive Porosität und eine
hohe spezifische Oberfläche. In seinem Chemismus und kristallinen
Aufbau ist es den Knochen wesentlich ähnlicher als andere
Knochenersatzmaterialien.
In einigen speziellen Anwendungen sind jedoch Knochenersatzmaterialien
erforderlich, die eine noch höhere Porosität und besonders
hohe mechanische Stabilität aufweisen. A hydroxyapatite material, which is obtained from the calcium carbonate skeleton of lime-encrusting algae, has proven itself as bone substitute material. Such a material is described in DE 37 09 897 C2. To produce molded articles, the granular hydroxyapatite material obtained by hydrothermal synthesis is shaken into a molded article with slaked lime as a binder and then subjected to a hydrothermal treatment again. The bone implant thus obtained has a high interconnectivity and a high specific surface area. In its chemistry and crystalline structure, it is much more similar to bones than other bone replacement materials.
In some special applications, however, bone replacement materials are required that have an even higher porosity and particularly high mechanical stability.
In der Veröffentlichung von Sada et al "Hydrothermal synthesis of crystalline hydroxylapatite ultrafine particles" in Chemical Engineering Communications, Bd. 103, 1991, Seiten 57 bis 64 wird die Herstellung von ultrafeinem Hydroxylapatitpulver beschrieben, in dem eine alkalische wäßrige Lösung je eines Calcium- und Phosphatsalzes in einem molaren Verhältnis von Ca:P von 1,67 zu einem nanokristallinen, gelartigem Hydroxylapatit umgesetzt wird, welches dann durch eine hydrothermale Behandlung in nanokristallines Hydroxylapatitpulver umgewandelt wird.In the publication by Sada et al "Hydrothermal synthesis of crystalline hydroxylapatite ultrafine particles "in Chemical Engineering Communications, Vol. 103, 1991, pages 57 to 64, the manufacture of described ultrafine hydroxyapatite powder in which an alkaline aqueous solution each of a calcium and Phosphate salt in a molar ratio of Ca: P from 1.67 to a nanocrystalline, gel-like Hydroxyapatite is implemented, which is then replaced by a hydrothermal treatment in nanocrystalline Hydroxyapatite powder is converted.
In der Veröffentlichung von Nonami et al. "Manufacture of bone substitue with porous hydroxylapatite and tricalcium phosphate", chemical abstracts, vol. 113, no.6, abstract no. 46344 und JP-A-01 293877 von TDK Corp. wird das Vermischen von porösem Hydroxylapatit und Calciumphosphat in einem Gewichtsverhältnis von 10:1 bis 1:10 beschrieben, wobei die Mischung anschließend unter hohem Druck und Wärmeeinwirkung in einen Formförper umgewandelt wird. In the Nonami et al. "Manufacture of bone substitue with porous hydroxylapatite and tricalcium phosphate ", chemical abstracts, vol. 113, no.6, abstract no. 46344 and JP-A-01 293877 by TDK Corp. is the mixing of porous hydroxyapatite and calcium phosphate in a weight ratio of 10: 1 to 1:10 described, the mixture then under high pressure and heat a shaped body is converted.
Aufgabe der Erfindung ist es, Materialien anzugeben, welche sich zur Herstellung eines Knochenersatzmaterials eignen, welches in seinem Chemismus und dem kristallinen Aufbau natürlichen Knochen möglichst ähnlich ist, eine sehr poröse Mikrostruktur aufweist, dabei aber eine hohe mechanische Stabilität besitzt. Die Materialien sollten einfach herstellbar, kostengünstig und gut verarbeitbar sein. Zusätzlich sollten sie es erlauben, bei ihrer Verarbeitung den Kristallphasen-Anteil und die Festigkeit des Knochenersatzmaterials gezielt einzustellen. The object of the invention is to provide materials which are suitable for producing a bone substitute material which, in its chemistry and crystalline structure, is as similar as possible to natural bones, has a very porous microstructure, but has high mechanical stability. The materials should be easy to manufacture, inexpensive and easy to process. In addition, they should allow the crystal phase portion and the strength of the bone substitute material to be specifically adjusted during processing.
Die Lösung dieser Aufgabe gelingt
der formbaren Hydroxylapatit-Masse gemäß Anspruch 1
und der verdichteten Hydroxylapatit-Masse gemäß Anspruch 14,
welche wiederum Bestandteil des erfindungsgemäßen Hydroxylapatit-Formkörpers
gemäß Anspruch 15 sind. Die Erfindung betrifft
weiterhin die Verwendung des Hydroxylapatit-Formkörpers gemäß
Anspruch 16. Der Hydroxylapatit-Formkörper ist ebenfalls als
Beschichtung in einem Metallimplantat gemäß Anspruch 19 vorhanden.
Außerdem betrifft die Erfindung ein Verfahren zur Herstellung
des Metallimplantats gemäß Anspruch 20,
sowie ein
Verfahren zur Herstellung des Hydroxylapatit-Formkörpers gemäß
Anspruch 22.
Weitere Verfahrensvarianten und Ausbildungsformen ergeben sich
aus den Unteransprüchen.This object is achieved by the mouldable hydroxylapatite composition according to claim 1 and the compressed hydroxylapatite composition according to claim 14, which in turn are part of the inventive hydroxylapatite molding according to claim 15. The invention further relates to the use of the hydroxyapatite molded body according to claim 16. The hydroxyapatite molded body is also present as a coating in a metal implant according to claim 19. In addition, the invention relates to a method for producing the metal implant according to claim 20, and to a method for producing the hydroxyapatite shaped body according to claim 22.
Further procedural variants and forms of training result from the subclaims.
In einem ersten Aspekt betrifft die Erfindung eine formbare Hydroxylapatit-Masse, welche durch einen Sol-Gel-Prozeß erhältlich ist. Dabei wird eine alkalische wässrige Lösung eines Calciumsalzes mit einer alkalischen wässrigen Lösung eines Phosphatsalzes zunächst'zu einem Sol umgesetzt. Die Stöchiometrie wird dabei derart gewählt, daß das Verhältnis von Calcium zu Phosphor dem Verhältnis im Hydroxylapatit entspricht. Das molare Verhältnis von Calcium zu Phosphor bei der Sol-Herstellung liegt also im Bereich von etwa 1,67. Anschließend wird das so erhaltene Sol durch hydrothermale Behandlung in ein Gel umgewandelt.In a first aspect, the invention relates to a moldable hydroxyapatite mass, which is obtainable by a sol-gel process. there becomes an alkaline aqueous solution of a calcium salt with an alkaline aqueous solution of a phosphate salt implemented a sol. The stoichiometry is included chosen such that the ratio of calcium to phosphorus Ratio in the hydroxyapatite corresponds. The molar ratio from calcium to phosphorus in sol production is therefore in the Range of approximately 1.67. Then the sol obtained in this way converted to a gel by hydrothermal treatment.
Der pH-Wert bei der Sol-Herstellung liegt vorzugsweise in einem Bereich von 9 bis 12 und besonders zweckmäßig zwischen 10,5 und 11. Der gewünschte pH-Bereich kann durch Zugabe der üblichen Basen eingestellt werden. Besonders geeignet hierfür ist Ammoniak. Es hat sich zudem als vorteilhaft herausgestellt, zunächst beide wässrigen Lösungen getrennt auf den gewünschten pH-Wert einzustellen und den pH-Wert, falls erforderlich, nach dem Mischen beider Lösungen nochmals in den gewünschten Bereich zu bringen.The pH in sol production is preferably one Range from 9 to 12 and particularly useful between 10.5 and 11. The desired pH range can be added by adding the usual Bases can be adjusted. Ammonia is particularly suitable for this. It also turned out to be advantageous, initially separate both aqueous solutions to the desired one Adjust the pH value and adjust the pH value if necessary mixing both solutions again in the desired range bring to.
Vorteilhafterweise erfolgt die Sol-Herstellung in einem Temperaturbereich zwischen 10° und 40°C, besonders zweckmäßig bei Raumtemperatur (20° bis 25°C).The sol is advantageously produced in a temperature range between 10 ° and 40 ° C, particularly useful at Room temperature (20 ° to 25 ° C).
Bei der Herstellung des Sols können beispielsweise 0,1 bis 1N
wässrige Lösungen des Calciumsalzes bzw. des Phosphatsalzes
verwendet werden. Besonders geeignet sind 0,3 bis 0,5N wässrige
Lösungen der Salze.
Als Ausgangsmaterialien können alle löslichen Calcium- und
Phosphatsalze eingesetzt werden, die möglichst keine körperunverträglichen
Bestandteile enthalten sollten. Ein geeignetes
Calciumsalz ist beispielsweise Calciumnitrat. Als Phosphatsalz
kann Diammoniumhydrogenphosphat verwendet werden.For example, 0.1 to 1N aqueous solutions of the calcium salt or the phosphate salt can be used in the preparation of the sol. 0.3 to 0.5N aqueous solutions of the salts are particularly suitable.
All soluble calcium and phosphate salts that should not contain any body-incompatible constituents can be used as starting materials. A suitable calcium salt is, for example, calcium nitrate. Diammonium hydrogen phosphate can be used as the phosphate salt.
Unter den genannten Bedingungen bildet sich das Sol nach dem Mischen der beiden wässrigen Lösungen durch Stehenlassen für einen Zeitraum von mehreren Tagen. In einem zweiten Schritt wird das Sol dann durch hydrothermale Behandlung in ein Gel umgewandelt. Die hydrothermale Behandlung erfolgt zweckmäßig in einem Temperaturbereich von 180 bis 200°C. Besonders vorteilhaft wird sie in einem Autoklaven durchgeführt. Geeignet sind insbesondere mit Polytetrafluorethylen oder ähnlichen inerten Auskleidungen beschichtete Autoklaven. Von Vorteil ist es, den Autoklaven maximal zu zwei Dritteln zu füllen und die hydrothermale Behandlung unter dem sich dann einstellenden Sättigungsdampfdruck der Lösung durchzuführen. Der pH-Wert bei der Umsetzung zum Gel liegt vorteilhafterweise im selben Bereich wie bei der Sol-Herstellung, also zwischen 9 und 12 und insbesondere zwischen 10,5 und 11.Under the conditions mentioned, the sol forms after the Mix the two aqueous solutions by standing for a period of several days. In a second step the sol is then converted to a gel by hydrothermal treatment. The hydrothermal treatment is advantageously carried out in a temperature range of 180 to 200 ° C. Particularly advantageous it is carried out in an autoclave. Are suitable especially with polytetrafluoroethylene or similar inert Linings coated autoclaves. It is an advantage that Fill autoclaves to a maximum of two thirds and the hydrothermal Treatment under the then occurring saturation vapor pressure the solution. The pH at Conversion to the gel is advantageously in the same range as in sol production, i.e. between 9 and 12 and in particular between 10.5 and 11.
Während der hydrothermalen Behandlung bilden sich in Sol Kristallkeime und feine Kristalle des Hydroxylapatits. Je nach Dauer der hydrothermalen Behandlung des Sols können die Kristallphasen-Anteile im Hydroxylapatit-Gel gezielt gesteuert werden. Auf diese Weise können die physikalischen Eigenschaften des Hydroxylapatit-Gels gezielt beeinflußt werden. Vorteilhaft erfolgt die hydrothermale Behandlung solange, bis der Anteil an Kristallkeimen und feinkristallinem Hydroxylapatit im Gel über 80 % und insbesondere etwa 90 % beträgt. In der Gelmasse bleiben bis zu zwei Drittel des im Sol enthaltenen Wassers erhalten. Üblicherweise enthält das erfindungsgemäße Gel nach seiner Herstellung bis zu 70 Gew.-% Wasser. Ein mittlerer Wassergehalt liegt bei etwa 60 Gew.-%. Läßt man das Hydroxylapatit-Gel längere Zeit stehen, setzt sich das Gel ab und es bildet sich ein wäßriger Überstand. Durch Abgießen dieses Überstandes läßt sich der Wassergehalt des Gels, falls gewünscht, gezielt verringern.During the hydrothermal treatment, crystal nuclei form in sol and fine crystals of hydroxyapatite. Depending on The duration of the hydrothermal treatment of the sol can be the crystal phase portions Controlled in the hydroxyapatite gel become. This way the physical properties of the hydroxyapatite gel can be influenced in a targeted manner. Advantageous the hydrothermal treatment continues until the proportion of Crystal nuclei and fine crystalline hydroxyapatite in the gel 80% and in particular about 90%. Remain in the gel mass preserve up to two thirds of the water contained in the sol. The gel according to the invention usually contains after its Production up to 70 wt .-% water. A medium water content is about 60% by weight. If you leave the hydroxyapatite gel longer Standing for a while, the gel settles and it forms aqueous supernatant. By pouring off this supernatant if desired, reduce the water content of the gel in a targeted manner.
Diese formbare Hydroxylapatit-Masse nach Anspruch 1, umfaßt neben dem oben beschriebenen Hydroxylapatit-Gel, welches als Bindemittel fungiert, einen calcium-haltigen granulären Füllstoff. Als Füllstoffe geeignet sind beispielsweise alle solchen, welche im Bereich der Knochenchirurgie bereits eingesetzt werden. Besonders geeignet als granulärer Füllstoff sind Hydroxylapatit-Materialien, welche aus kalkinkrustierenden Algen gewonnen werden. Beispiele sind im deutschen Patent 37 09 897 beschrieben. In den dort beschriebenen Materialien bleibt das Calciumcarbonat-Skelett der Algen erhalten, so daß das Material eine hohe interkonnektive Porosität und eine große spezifische Oberfläche aufweist.This malleable Hydroxyapatite composition according to claim 1, comprising in addition to the above-described hydroxylapatite gel, which acts as a binder, a calcium-containing granular filler. Suitable as fillers are, for example, all those in the field of bone surgery are already in use. Particularly suitable as granular filler are hydroxyapatite materials which can be obtained from lime-encrusting algae. examples are described in German Patent 37 09 897. In those described there The calcium carbonate skeleton remains the materials Preserve algae so that the material has a high interconnectivity Porosity and has a large specific surface.
Als granulärer Füllstoff für die formbare Hydroxylapatit-Masse kann auch ein modifiziertes, Tricalciumphosphat-haltiges Hydroxylapatit-Material verwendet werden, das erhältlich ist durch Umsetzen eines von organischen Verbindungen befreiten Algen-Hartgewebes in einer alkalischen wässrigen Phosphat-Lösung unter Zusatz von Mg2+-Ionen bei erhöhter Temperatur. Ein derartiges Material ist in einer parallelen deutschen Patentanmeldung der Anmelderin beschrieben. Dieses Tricalciumphosphathaltige Hydroxylapatit-Material weist vorteilhaft einen Tricalciumphosphat-Gehalt von 20 bis 90 Gew.% auf. Das Algen-Hartgewebe wird, wie im Fall der nichtmodifizierten Hydroxylapatit-Materialien, zweckmäßig aus kalkinkrustierenden Meeresalgen gewonnen, insbesondere aus solchen der Spezies Corallinacea oder Codiacea.A modified, tricalcium phosphate-containing hydroxylapatite material can also be used as the granular filler for the moldable hydroxylapatite mass, which is obtainable by converting an algae hard tissue freed from organic compounds into an alkaline aqueous phosphate solution with the addition of Mg 2+ - Ions at elevated temperature. Such a material is described in a parallel German patent application by the applicant. This tricalcium phosphate-containing hydroxyapatite material advantageously has a tricalcium phosphate content of 20 to 90% by weight. The hard algae tissue, as in the case of the unmodified hydroxyapatite materials, is expediently obtained from calcareous seaweed, in particular from those of the species Corallinacea or Codiacea.
In der formbaren Hydroxylapatit-Masse können das erfindungsgemäße Hydroxylapatit-Gel und der granuläre Feststoff in einem breiten Mengenverhältnis miteinander gemischt werden. Geeignet sind beispielsweise Gewichtsverhältnisse von Hydroxylapatit-Gel und granulärem Feststoff zwischen 10:1 und 1:10, wobei hier von einem Hydroxylapatit-Gel mit einem Wassergehalt von etwa 60 Gew.-% ausgegangen wird. Die jeweiligen Anteile werden entsprechend der gewünschten späteren Verwendung der erfindungsgemäßen formbaren Hydroxylapatit-Masse gewählt. Auch die Art und Weise, auf welche die formbare Masse verarbeitet werden soll, spielt bei der Auswahl der Anteile der beiden Komponenten eine Rolle. Bei der Verwendung der erfindungsgemäßen formbaren Hydroxylapatit-Masse für eine Beschichtung können höhere Anteile an Gel die Verarbeitung erleichtern. Formkörper allein aus Hydroxylapatit-Masse - beispielsweise Knochenersatzmaterialien, welche eine hohe mechanische Festigkeit besitzen müssen - werden üblicherweise einen höheren Anteil an granulärem Feststoff enthalten. Für letztere sind beispielsweise Gewichtsverhältnisse von Gel zu Feststoff zwischen 1:5 und 1:8 verwendbar.In the moldable hydroxyapatite mass, the invention Hydroxyapatite gel and the granular solid in one wide proportions can be mixed. Suitable are, for example, weight ratios of hydroxyapatite gel and granular solid between 10: 1 and 1:10, here of a hydroxyapatite gel with a water content of about 60 % By weight is assumed. The respective shares will be accordingly the desired later use of the invention malleable hydroxyapatite mass selected. Also the way on which the malleable mass is to be processed plays a role in the selection of the proportions of the two components. When using the moldable hydroxyapatite composition according to the invention higher proportions of gel can be used for a coating make processing easier. Shaped body solely from the mass of hydroxyapatite - For example, bone replacement materials, which have a high mechanical strength - are usually contain a higher proportion of granular solid. For the latter, for example, weight ratios of Gel to solid between 1: 5 and 1: 8 can be used.
Die erfindungsgemäße formbare Hydroxylapatit-Masse kann weitere Komponenten enthalten, wie sie beispielsweise bei Knochenersatzmaterialien oder Filtermaterialien üblich sind. Für Knochenersatzmaterial kann es beispielsweise zweckmäßig sein, der Masse wenigstens einen Wirkstoff zuzusetzen. Beispiele sind wachstumsfördernde oder -hemmende Substanzen. Spezielle Beispiele sind Antibiotika, Chemotherapeutika, tumorhemmende Verbindungen und knocheninduktive Substanzen. Beispielhaft für letztere können knochenmorphogene Proteine (bone morphogenic proteins) genannt werden. Diese Wirkstoffe können in die erfindungsgemäße Masse eingearbeitet werden, oder sie werden auf den fertigen, aus der erfindungsgemäßen Masse hergestellten Formkörper aufgetragen. Zweckmäßig wird für jeden Wirkstoff die jeweils klinisch aktive Menge verwendet.The moldable hydroxylapatite composition according to the invention can be further Contain components such as those found in bone substitute materials or filter materials are common. For bone replacement material it may be appropriate, for example, the Add mass at least one active ingredient. examples are growth promoting or inhibiting substances. Specific examples are antibiotics, chemotherapy drugs, anti-tumor compounds and bone inductive substances. Exemplary for the latter can be bone morphogenic proteins (bone morphogenic proteins). These active ingredients can be used in the invention Be incorporated, or they will be on the finished moldings produced from the composition according to the invention applied. The appropriate for each active ingredient clinically active amount used.
Die erfindungsgemäße formbare Hydroxylapatit-Masse ist durch ihren Anteil an Hydroxylapatit-Gel beliebig formbar. Dies erleichtert erheblich die Herstellung auch kompliziert aufgebauter Formkörper. Wenn als granulärer Füllstoff ein aus kalkinkrustierenden Algen gewonnenes Hydroxylapatit-Material verwendet wird, wird eine formbare Masse erhalten, die praktisch ausschließlich aus Hydroxylapatit besteht. Die aus dieser Masse hergestellten Formkörper sind nicht nur außerordentlich körperverträglich, sondern sie besitzen auch eine außergewbhnlich poröse Mikrostruktur bei gleichzeitig hoher mechanischer Stabilität. Die erfindungsgemäße Hydroxylapatit-Masse ist deshalb außerordentlich gut zur Herstellung von Knochenersatzmaterialien geeignet. Zudem lassen sich die physikalischen Eigenschaften der formbaren Masse und infolgedessen auch der aus ihr hergestellten Formkörper gezielt beeinflussen. The moldable hydroxyapatite composition according to the invention is through any proportion of hydroxyapatite gel malleable. This considerably simplifies the manufacture, even in a complicated manner assembled molded body. If as a granular filler a hydroxyapatite material obtained from limestone encrusting algae a malleable mass is obtained which consists almost exclusively of hydroxyapatite. From this mass of molded articles are not only extraordinary body-friendly, but they also have one exceptionally porous microstructure with high mechanical Stability. The hydroxyapatite mass according to the invention is therefore extremely good for the production of bone replacement materials suitable. In addition, the physical Properties of the malleable mass and as a result also specifically influence the molded body produced from it.
Beispielsweise ist es möglich, die Hydroxylapatit-Masse unter Druck zu komprimieren und damit ihre Dichte und ihre Festigkeit zu erhöhen. Wendet man zum Komprimieren einen Druck an, der 1 MPa nicht übersteigt, bleibt die poröse Mikrostruktur der Masse dabei erhalten.For example, it is possible to lower the hydroxyapatite mass Compress pressure and thus its density and strength to increase. If you apply a pressure to compress that 1 Does not exceed MPa, the porous microstructure of the mass remains received in the process.
Auf die Steuerung der Kristallphasen-Anteile im Gel - und damit auch in der das Gel enthaltenden formbaren Hydroxylapatit-Masse - war bereits hingewiesen worden. Die Kristallinität kann weiterhin über die Art und Dauer der thermischen Behandlung der formbaren Hydroxylapatit-Masse beeinflußt werden, mit der aus der Masse ein fester Formkörper erzeugt wird.On the control of the crystal phase proportions in the gel - and thus also in the malleable hydroxyapatite mass containing the gel - had already been pointed out. The crystallinity can continue about the type and duration of the thermal treatment of the malleable hydroxyapatite mass are affected with the a solid molded body is produced.
Zu diesem Zweck wird die erfindungsgemäße formbare Hydroxylapatit-Masse in eine geeignete Form gefüllt und vor dem Aushärten zweckmäßig zunächst entgast. Geeignet ist hierzu beispielsweise eine Behandlung durch Ultraschall. Um eine größere Dichte und höhere Festigkeit zu erreichen, kann die formbare Masse, wie erwähnt, komprimiert werden. Die thermische Behandlung zum Aushärten der Masse erfolgt zweckmäßig in einem Temperaturbereich zwischen 500° und 650°C, insbesondere zwischen 550° und 600°C. Die Dauer der thermischen Behandlung richtet sich nach der Zusammensetzung der formbaren Masse und der Größe des Formkörpers. Üblicherweise wird die Zeit der Behandlung zwischen etwa einer halben Stunde und mehreren Stunden betragen. Falls erforderlich, kann der hergestellte erfindungsgemäße Formkörper mit üblichen OP-Werkzeugen nachbearbeitet und in seine endgültige Form gebracht werden. Außerdem können Beschichtungen, wie solche aus knocheninduktiven Verbindungen, die bereits erwähnt wurden, auf den erfindungsgemäßen Hydroxylapatit-Formkörper aufgebracht werden.For this purpose, the moldable hydroxyapatite composition according to the invention filled into a suitable form and before curing first degassed appropriately. For example, this is suitable treatment by ultrasound. To a greater density and to achieve higher strength, the malleable mass, as mentioned, be compressed. The thermal treatment for The mass is expediently cured in a temperature range between 500 ° and 650 ° C, especially between 550 ° and 600 ° C. The duration of the thermal treatment depends on the composition of the moldable mass and the size of the molded body. Usually the time of treatment is between about half an hour and several hours. If required, the molded body according to the invention produced reworked with usual surgical tools and into its final Be brought into shape. In addition, coatings such as those from bone-inductive compounds, which have already been mentioned were, on the shaped hydroxyapatite body according to the invention be applied.
Wegen der sehr porösen Mikrostruktur bei hoher mechanischer Festigkeit eignet sich der erfindungsgemäße Hydroxylapatit-Formkörper ausgezeichnet zur Verwendung im Bereich der Knochenchirurgie, insbesondere als Knochenersatzmaterial oder als Trägermaterial für Wirkstoffe. Wegen ihrer porösen Struktur können die erfindungsgemäßen Formkörper jedoch auch als Filtermaterialien eingesetzt werden.Because of the very porous microstructure with high mechanical strength the shaped hydroxyapatite body according to the invention is suitable excellent for use in the field of bone surgery, in particular as a bone replacement material or as a carrier material for active substances. Because of their porous structure can however, the moldings according to the invention also as filter materials be used.
Die erfindungsgemäßen Hydroxylapatit-Formkörper eignen sich außerdem als bioaktive Beschichtung auf Metallimplantaten und insbesondere auf Titanknochenimplantaten. Die Erfindung betrifft in einem weiteren Aspekt ein derartiges Metallimplantat, welches eine Beschichtung aus dem erfindungsgemäßen Hydroxylapatit-Formkörper umfaßt. Zur Herstellung des Implantats wird auf die Metalloberfläche eine Schicht aus der erfindungsgemäßen formbaren Hydroxylapatit-Masse aufgebracht und diese einer thermischen Behandlung zwischen 500° und 650°C unterzogen, wie dies vorstehend beschrieben wurde. Um die Haftung der Beschichtung auf der Metalloberfläche zu verbessern, wird diese Oberfläche zweckmäßig vor ihrer Beschichtung behandelt. Derartige Behandlungen zur Haftungsverbesserung sind für Metallimplantate bekannt. Diese bekannten Oberflächenbehandlungsverfahren können auch vor Aufbringung der erfindungsgemäßen Beschichtung angewendet werden. Bevorzugt wird jedoch eine Behandlung durchgeführt, die ebenfalls Gegenstand dieser Erfindung ist.The hydroxyapatite moldings according to the invention are suitable also as a bioactive coating on metal implants and especially on titanium bone implants. The invention relates in a further aspect, such a metal implant, which is a coating of the molded hydroxyapatite according to the invention includes. To manufacture the implant on the metal surface a layer of the invention malleable hydroxyapatite mass applied and this one subjected to thermal treatment between 500 ° and 650 ° C, such as this has been described above. To the adhesion of the coating to improve on the metal surface, this surface appropriately treated before their coating. such Treatments to improve adhesion are for metal implants known. These known surface treatment methods can also applied before applying the coating according to the invention become. However, treatment is preferably carried out which is also the subject of this invention.
Im bevorzugten erfindungsgemäßen Verfahren zur Herstellung eines
Metallimplantats wird die Oberfläche des Metalls vor Aufbringung
der Beschichtung in einer Elektrolytlösung unter Funkenentladung
bei einer Temperatur zwischen -10 und -20°C oxidiert,
bis die Dicke der Oxidschicht zwischen 25 und 40 µm beträgt.
Die Oxidation erfolgt bei Wechselstrom von 50 Hz bei einer
Spannung zwischen 110 und 200 V. Die verwendete wäßrige
Elektrolytlösung umfaßt:
Als Oxidationsmittel werden bevorzugt die Alkalisalze der
Chlorsauerstoffsäuren verwendet, hier inbesondere die Chlorate
und Chlorite wie Natriumchlorat oder Natriumchlorit. Es können
auch Gemische verschiedener Salze verwendet werden. Von den übrigen
Säuren werden vorzugsweise die Alkali- oder Ammoniumsalze
verwendet. Beispiele bevorzugter Verbindungen sind Natriumfluorid,
Ammoniumfluorid, Kaliumdihydrogenphosphat und Natriumperborat.
Als Amin werden zweckmäßig aliphatische Amine oder Alkohol-Amine
eingesetzt, bevorzugt Triethylamin oder Triethanolamin.The alkali metal salts of chlorine oxygen acids are preferably used as the oxidizing agent, in particular the chlorates and chlorites such as sodium chlorate or sodium chlorite. Mixtures of different salts can also be used. Of the other acids, the alkali or ammonium salts are preferably used. Examples of preferred compounds are sodium fluoride, ammonium fluoride, potassium dihydrogen phosphate and sodium perborate.
Aliphatic amines or alcohol amines are advantageously used as the amine, preferably triethylamine or triethanolamine.
Die gemäß dem erfindungsgemäßen Verfahren erhaltene Oxidschicht wird anschließend in einem Brennprozeß rekristallisiert. Zweckmäßig wird die Oxidschicht nach dem Trocknen für 20 bis 40 Minuten einer Temperatur von 550 bis 650°C ausgesetzt. Von Vorteil werden die eventuell noch auf der Oxidschicht befindlichen ungebundenen Ionen mit destilliertem Wasser entfernt, bevor die erfindungsgemäße formbare Masse auf die behandelte Metalloberfläche aufgetragen wird. Zweckmäßig beträgt die Schichtdicke 5 bis 10 µm. Die thermische Behandlung der formbaren Masse erfolgt wie vorstehend beschrieben.The oxide layer obtained according to the inventive method is then recrystallized in a firing process. expedient the oxide layer after drying for 20 to 40 minutes exposed to a temperature of 550 to 650 ° C. Advantageous are those that may still be on the oxide layer unbound ions removed with distilled water before the Mouldable composition according to the invention on the treated metal surface is applied. The layer thickness is expediently 5 up to 10 µm. The moldable mass is thermally treated as described above.
Die Erfindung soll nachfolgend anhand einiger Beispiele näher erläutert werden. The invention is illustrated below with the aid of a few examples are explained.
Eine 0,5N wässrige Lösung von Ca(NO3)2·4H2O und eine 0,3N wäßrige
Lösung von (NH4)2HPO4 werden getrennt voneinander mit Ammoniak
auf einen pH-Wert von 10,5 eingestellt. Beide Lösungen werden
im Verhältnis 1:1 unter Rühren gründlich gemischt. Der pH-Wert
der so erhaltenen Lösung wird, falls erforderlich, erneut
mit Ammoniak auf 10,5 gebracht.
Die Reaktionsmischung wird bei einer Temperatur zwischen 20°
und 25°C fünf bis sechs Tage stehengelassen. Während dieser
Zeit bildet sich ein primäres Apatit-Sol.A 0.5N aqueous solution of Ca (NO 3 ) 2 .4H 2 O and a 0.3N aqueous solution of (NH 4 ) 2 HPO 4 are adjusted separately to a pH of 10.5 with ammonia. Both solutions are mixed thoroughly in a 1: 1 ratio with stirring. If necessary, the pH of the solution thus obtained is brought to 10.5 again with ammonia.
The reaction mixture is left to stand at a temperature between 20 ° and 25 ° C for five to six days. During this time, a primary apatite sol forms.
Zur Herstellung eines Gels wird das Sol bei 180 bis 200°C hydrothermal behandelt. Hierzu wird das Gel in einen mit PTFE ausgekleideten Autoklaven überführt, der maximal zu zwei Dritteln befüllt wird. Die hydrothermale Behandlung erfolgt unter dem Sättigungsdampfdruck der Lösung. Die Behandlung wird solange fortgesetzt, bis sich wenigstens 80% Kristallkeime und feinkristalliner Hydroxylapatit gebildet haben. Vorzugsweise wird die hydrothermale Behandlung fortgesetzt, bis sich etwa 90% Kristallkeime und feinkristalliner Hydroxylapatit gebildet haben. Die hydrothermale Behandlung erfordert üblicherweise wenigstens 24 Stunden. Nach etwa 30 Stunden Reaktionszeit ist keine wesentliche Änderung der Kristallinität mehr zu beobachten. Das erhaltene Hydroxylapatit-Gel besitzt einen Wasseranteil von etwa 60 Gew.-%.To produce a gel, the sol becomes hydrothermal at 180 to 200 ° C treated. To do this, the gel is placed in a PTFE lined autoclave, the maximum of two thirds is filled. The hydrothermal treatment takes place under the saturated vapor pressure of the solution. Treatment continues continued until at least 80% crystal nuclei and fine crystalline Have formed hydroxyapatite. Preferably continue hydrothermal treatment until about 90% Crystal nuclei and fine crystalline hydroxyapatite have formed. The hydrothermal treatment usually requires at least 24 hours. After about 30 hours of reaction time no significant change in crystallinity was observed. The hydroxyapatite gel obtained has a water content of about 60% by weight.
Das erhaltene Hydroxylapatit-Gel wird mit einem gemäß deutschem Patent 37 09 897 aus kalkinkrustierenden Rotalgen hergestellten granulären Hydroxylapatit-Material in einem Gewichtsverhältnis von 1:10 gemischt. Es wird eine homogene teigartige Masse erhalten.The hydroxyapatite gel obtained is treated with a according to German patent 37 09 897 made from red algae encrusted with lime Granular hydroxyapatite material produced in one Weight ratio of 1:10 mixed. It will be a homogeneous one get pasty mass.
Die erhaltene Hydroxylapatit-Masse wird in eine Preßform gefüllt. Sie wird durch Bestrahlung mit Ultraschall entlüftet und bei einem Druck von 0,9 MPa einige Minuten lang verdichtet. Anschließend wird die verdichtete Masse in der Preßform in einem Ofen bei 550 bis 600°C etwa 60 Minuten lang thermisch behandelt. Auf diese Weise wird ein Formkörper mit einer sehr porösen Mikrostruktur und hoher mechanischer Festigkeit erhalten. Er läßt sich mechanisch nachbearbeiten.The resulting hydroxyapatite mass is in a Mold filled. It is done by ultrasound radiation vented and at a pressure of 0.9 MPa for a few minutes compacted. Then the compacted mass in the Press mold in an oven at 550 to 600 ° C for about 60 minutes thermally treated. In this way, a molded body with a very porous microstructure and high mechanical strength receive. It can be reworked mechanically.
Ein Titan-Knochenimplantat wird unter Funkenentladung in einer
Elektrolytlösung bei -10°C oxidiert. Die Lösung enthält:
Die Oxidation wird bei einer Spannung von 160 V 5 Minuten lang durchgeführt. Dann wird das behandelte Implantat aus der Lösung entfernt, und die erzeugte Oxidschicht wird bei 600°C in einem Ofen zwanzig Minuten lang rekristallisiert. Anschließend wird mehrfach mit kochendem destillierten Wasser gespült, bis alle nicht gebundenen Ionen völlig vom Implantat entfernt sind.The oxidation is carried out at a voltage of 160 V for 5 minutes carried out. Then the treated implant comes out of solution removed, and the oxide layer produced is at 600 ° C in one Oven recrystallized for twenty minutes. Then will rinsed several times with boiling distilled water until all unbound ions are completely removed from the implant.
Die Oberfläche des Titan-Knochenimplantats wird unter Funkenentladung
in einer Elektrolytlösung bei -15°C oxidiert. Die Lösung
besteht aus:
Die Durchführung des Verfahrens erfolgt wie unter Punkt 1, jedoch bei einer Spannung von 180 V 3,5 Minuten lang. Analog Punkt 1 erfolgt die Rekristallisation der Oxidschicht bei 580°C für 30 Minuten. Die Nachbehandlung entspricht ebenfalls Punkt 1.The procedure is carried out as in point 1, however at a voltage of 180 V for 3.5 minutes. Analogous Point 1, the oxide layer is recrystallized at 580 ° C for 30 minutes. The after-treatment also corresponds to point 1.
Das gemäß Punkt 1 oder 2 behandelte Metallimplantat wird mit einer Beschichtung versehen, die besteht aus einem Hydroxylapatit-Gel wie oben beschrieben und einem gemäß deutschem Patent 37 09 897 hergestellten Hydroxylapatit-Granulat in einem Volumenverhältnis von 2:0,75. Die Schichtdicke beträgt etwa 7 µm. Nach dem Trocknen der Schicht wird diese bei 550°C in einem Ofen 40 Minuten lang fixiert.The metal implant treated according to item 1 or 2 is included provided a coating that consists of a Hydroxyapatite gel as described above and one according to German Patent 37 09 897 produced hydroxyapatite granules in a volume ratio of 2: 0.75. The layer thickness is about 7 µm. After drying, the layer is at 550 ° C fixed in an oven for 40 minutes.
Es wird wie unter Punkt 3 beschrieben vorgegangen, jedoch beträgt das Verhältnis von Hydroxylapatit-Gel zu Granulat 2:1. Die Fixierung der Schicht erfolgt 30 Minuten lang bei 500°C.The procedure is as described under point 3, but the the ratio of hydroxyapatite gel to granules 2: 1. The layer is fixed at 500 ° C. for 30 minutes.
In beiden Fällen wird eine Beschichtung mit außerordentlich guten bioaktiven Eigenschaften erhalten. Die Beschichtung ist gut mit der Metalloberfläche verbunden. Das erfindungsgemäße beschichtete Metallimplantat ergab in klinischen Untersuchungen äußerst günstige Bedingungen für eine Knochenaugmentation und eine gute Befestigung des neu gebildeten Knochengewebes an der Oberfläche.In both cases, a coating with is extraordinary maintain good bioactive properties. The coating is well connected to the metal surface. The invention coated metal implant revealed in clinical trials extremely favorable conditions for a bone augmentation and a good attachment of the newly formed bone tissue to the Surface.
Claims (25)
- A moldable hydroxylapatite composition, which comprises a calcium-containing granular filler and a hydroxylapatite gel which is obtainable by a sol-gel process in which an alkaline aqueous solution of a calcium salt is reacted with an alkaline aqueous solution of a phosphate salt with a molar ratio of calcium to phosphorus in the region of 1.67 to give a sol, and the sol is converted by hydrothermal treatment into a gel.
- A moldable hydroxylapatite composition as claimed in claim 1, wherein the pH during the production of the sol is in a range from 9 to 12 and, in particular, from 10.5 to 11.
- A moldable hydroxylapatite composition as claimed in claim 1 or 2, wherein the sol is produced at from 10°C to 40°C and, in particular, at from 20°C to 25°C.
- A moldable hydroxylapatite composition as claimed in any of claims 1 to 3, wherein 0.1 to 1 N aqueous solutions of the calcium salt and of the phosphate salt and, in particular, 0.3 to 0.5 N aqueous solutions are employed.
- A moldable hydroxylapatite composition as claimed in any of claims 1 to 4, wherein calcium nitrate is employed as calcium salt.
- A moldable hydroxylapatite composition as claimed in any of claims 1 to 5, wherein diammonium hydrogen phosphate is employed as phosphate salt.
- A moldable hydroxylapatite composition as claimed in any of claims 1 to 6, wherein the hydrothermal treatment takes place at from 180°C to 200°C.
- A moldable hydroxylapatite composition as claimed in claim 7, wherein the hydrothermal treatment takes place until the proportion of crystal nuclei and microcrystalline hydroxylapatite is above 80% and, in particular, about 90%.
- A moldable hydroxylapatite composition as claimed in any of claims 1 to 8, wherein a hydroxylapatite material obtained from calcareous algae is used as granular filler.
- A moldable hydroxylapatite composition as claimed in claim 9, wherein a tricalcium phosphate-containing hydroxylapatite material which is obtainable by reacting an algal hard tissue, from which organic compounds have been removed, in an alkaline aqueous phosphate solution with addition of Mg2+ ions at elevated temperature is used as granular filler.
- A moldable hydroxylapatite composition as claimed in claim 10, wherein the tricalcium phosphate content is from 20 to 90% by weight based on the granular filler.
- A moldable hydroxylapatite composition as claimed in any of claims 8 to 11, wherein hydroxylapatite gel and granular filler are present in a ratio of from 10:1 to 1:10 and, in particular, from 1:5 to 1:8 by weight.
- A moldable hydroxylapatite composition as claimed in any of claims 1 to 12, which comprises at least one substance, in particular a growth-promoting or growth-inhibiting compound, an antibiotic, a chemotherapeutic agent, a tumor-inhibiting compound or a bone-inductive compound, in particular at least one bone morphogenic protein.
- A compacted hydroxylapatite composition obtainable by compression of the moldable hydroxylapatite composition as claimed in any of claims 1 to 13 under a pressure of up to 1 MPa.
- A hydroxylapatite molding obtainable by thermal treatment of the hydroxylapatite composition as claimed in any of claims 1 to 14 at a temperature of from 500°C to 650°C and, in particular, from 550°C to 600°C.
- The use of the hydroxylapatite molding as claimed in claim 15 in bone surgery, in particular as bone substitute material or as carrier material for active substances, and as filter material.
- The use of the hydroxylapatite molding as claimed in claim 16 as carrier material for growth-promoting or growth-inhibiting compounds, an antibiotic, a chemotherapeutic agent, a tumor-inhibiting compound or a bone-inductive compound, in particular at least one bone morphogenic protein.
- The use as claimed in claim 16 or 17 as bioactive coating on metal implants and, in particular, on titanium bone implants.
- A metal implant, in particular titanium bone implant, which comprises a coating of the hydroxylapatite molding as claimed in claim 15.
- A process for producing a metal implant, in particular a titanium bone implant, as claimed in claim 19, which comprises applying to the surface of the metal implant a layer of the moldable hydroxylapatite composition as claimed in any of claims 1 to 13, and subjecting the latter to a thermal treatment at a temperature between 500°C and 650°C.
- The process as claimed in claim 20, wherein the surface of the metal implant is, before application of the coating, oxidized in an electrolyte solution with spark discharge at a temperature between -10°C and -20°C until the thickness of the oxide layer is between 25 and 40 µm, the oxidation taking place with a 50 Hz alternating current and with a voltage of 110 V to 200 V in an electrolyte solution which comprises:
polyethylene glycol (molecular weight 200 to 400) 80 to 200 ml/l at least one chlorine oxoacid or salt thereof 5 to 20 g/l and amine 10 to 30 ml/l and/or hydrofluoric acid or salts thereof 2 to 25 g/l and/or phosphoric acid or salts thereof 20 to 80 g/l and/or perboric acid or salts thereof 10 to 40 g/l - A process for producing a hydroxylapatite molding as claimed in claim 15, which comprises a calcium-containing granular filler and hydroxylapatite gel being mixed together and subjected to a thermal treatment at a temperature of from 500°C to 650°C and, in particular, of from 550°C to 600°C.
- The process as claimed in claim 22, wherein the hydroxylapatite composition is degassed before the thermal treatment and is, in particular, degassed by exposure to ultrasound.
- The process as claimed in claim 22 or 23, wherein the hydroxylapatite composition is compressed before the thermal treatment.
- The process as claimed in claim 24, wherein the molding is treated in a compression mold under a pressure of up to 1 MPa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG101544A BG101544A (en) | 1997-05-30 | 1997-05-30 | Method for the preparation of biologically active coatings over titanium osteal implants |
| BG10154497 | 1997-05-30 | ||
| PCT/EP1998/003093 WO1998054089A1 (en) | 1997-05-30 | 1998-05-26 | Hydroxylapatite gel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0984901A1 EP0984901A1 (en) | 2000-03-15 |
| EP0984901B1 true EP0984901B1 (en) | 2003-07-30 |
Family
ID=3927044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98934899A Expired - Lifetime EP0984901B1 (en) | 1997-05-30 | 1998-05-26 | Hydroxylapatite gel |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6428803B1 (en) |
| EP (1) | EP0984901B1 (en) |
| AT (1) | ATE246146T1 (en) |
| AU (1) | AU8434898A (en) |
| BG (1) | BG101544A (en) |
| CA (1) | CA2291677A1 (en) |
| DE (1) | DE59809162D1 (en) |
| ES (1) | ES2209166T3 (en) |
| WO (1) | WO1998054089A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19950113A1 (en) * | 1999-10-18 | 2001-05-03 | Jordanova Spassova Margarita | Hydroxyapatite material containing tricalcium phosphate |
| US6881227B2 (en) | 1999-11-30 | 2005-04-19 | Margarita Jordanova-Spassova | Hydroxylapatite material containing tricalcium phosphate with microporous structure |
| FI20010523A0 (en) * | 2001-03-16 | 2001-03-16 | Yli Urpo Antti | Treatment of sols, gels and mixtures thereof |
| EP2295089B1 (en) | 2002-07-31 | 2018-05-09 | DENTSPLY SIRONA Inc. | Bone repair putty comprising porous particulate and carrier gel |
| US8876532B2 (en) | 2002-07-31 | 2014-11-04 | Dentsply International Inc. | Bone repair putty |
| BG65595B1 (en) * | 2002-11-04 | 2009-02-27 | Лиляна ПРАМАТАРОВА | Method for growing of hydroxyapatite layers by a system materializing the laser-solution-substrate interaction |
| US7067169B2 (en) * | 2003-06-04 | 2006-06-27 | Chemat Technology Inc. | Coated implants and methods of coating |
| US7419680B2 (en) * | 2003-10-01 | 2008-09-02 | New York University | Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate |
| US9199005B2 (en) * | 2003-10-01 | 2015-12-01 | New York University | Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate |
| SE527610C2 (en) * | 2004-06-15 | 2006-04-25 | Promimic Ab | Process for the preparation of synthetic crystalline calcium phosphate in nano size |
| WO2006031196A1 (en) * | 2004-09-14 | 2006-03-23 | Agency For Science, Technology And Research | Porous biomaterial-filler composite and a method for making the same |
| US7785648B2 (en) * | 2004-09-22 | 2010-08-31 | New York University | Adherent apatite coating on titanium substrate using chemical deposition |
| WO2006039400A2 (en) | 2004-09-29 | 2006-04-13 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
| CN101340935B (en) | 2005-11-14 | 2013-05-08 | 拜奥美特3i有限责任公司 | Deposition of discrete nanoparticles on an implant surface |
| US8287914B2 (en) * | 2006-01-12 | 2012-10-16 | Rutgers, The State University Of New Jersey | Biomimetic hydroxyapatite synthesis |
| US20100040668A1 (en) * | 2006-01-12 | 2010-02-18 | Rutgers, The State University Of New Jersey | Biomimetic Hydroxyapatite Composite Materials and Methods for the Preparation Thereof |
| ES2545781T3 (en) | 2008-01-28 | 2015-09-15 | Biomet 3I, Llc | Superficial implant with greater hydrophilicity |
| US8641418B2 (en) | 2010-03-29 | 2014-02-04 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
| US9089382B2 (en) | 2012-01-23 | 2015-07-28 | Biomet 3I, Llc | Method and apparatus for recording spatial gingival soft tissue relationship to implant placement within alveolar bone for immediate-implant placement |
| US9452032B2 (en) | 2012-01-23 | 2016-09-27 | Biomet 3I, Llc | Soft tissue preservation temporary (shell) immediate-implant abutment with biological active surface |
| WO2013142118A1 (en) | 2012-03-20 | 2013-09-26 | Biomet 3I, Llc | Surface treatment for an implant surface |
| US9700390B2 (en) | 2014-08-22 | 2017-07-11 | Biomet 3I, Llc | Soft-tissue preservation arrangement and method |
| DE102015101626B4 (en) * | 2015-02-04 | 2019-06-27 | Kulzer Gmbh | Coating of dental prosthetic surfaces with a distinct layer of a synthetic hydroxyapatite |
| US10449018B2 (en) | 2015-03-09 | 2019-10-22 | Stephen J. Chu | Gingival ovate pontic and methods of using the same |
| CN115382011A (en) * | 2021-07-01 | 2022-11-25 | 意瑞生物科技(苏州)有限公司 | Skin injection filler gel and preparation process thereof |
| CN114057173B (en) * | 2021-09-13 | 2023-12-15 | 曲阜师范大学 | A method for synthesizing large specific surface area hydroxyapatite using crystal seeds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207306A (en) * | 1974-08-02 | 1980-06-10 | Sterling Drug Inc. | Process for producing polycrystalline ceramic oxides |
| JPH0669482B2 (en) * | 1985-08-08 | 1994-09-07 | 住友化学工業株式会社 | Intraosseous implant manufacturing method |
| DE3542744C1 (en) * | 1985-12-03 | 1987-05-27 | Ewers Rolf | Porous hydroxyapatite material |
| DE3709897A1 (en) * | 1987-03-26 | 1988-10-06 | Ewers Rolf | METHOD OF MANUFACTURING A HYDROXYLAPATITE MATERIAL |
| JPH01293877A (en) * | 1988-05-24 | 1989-11-27 | Tdk Corp | Preparation of artificial bone material |
| US5071655A (en) * | 1990-01-12 | 1991-12-10 | Baylink David J | Pharmaceutical combination for treatment of bone-wasting diseases |
| JP3140452B2 (en) * | 1990-07-05 | 2001-03-05 | 石福金属興業株式会社 | Surface treatment method for implantable material in vivo |
| JPH0747116A (en) * | 1993-08-05 | 1995-02-21 | Nikon Corp | Implant manufacturing method |
-
1997
- 1997-05-30 BG BG101544A patent/BG101544A/en unknown
-
1998
- 1998-05-26 CA CA002291677A patent/CA2291677A1/en not_active Abandoned
- 1998-05-26 EP EP98934899A patent/EP0984901B1/en not_active Expired - Lifetime
- 1998-05-26 DE DE59809162T patent/DE59809162D1/en not_active Expired - Fee Related
- 1998-05-26 AU AU84348/98A patent/AU8434898A/en not_active Abandoned
- 1998-05-26 WO PCT/EP1998/003093 patent/WO1998054089A1/en not_active Ceased
- 1998-05-26 ES ES98934899T patent/ES2209166T3/en not_active Expired - Lifetime
- 1998-05-26 AT AT98934899T patent/ATE246146T1/en not_active IP Right Cessation
-
1999
- 1999-11-30 US US09/451,691 patent/US6428803B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2209166T3 (en) | 2004-06-16 |
| DE59809162D1 (en) | 2003-09-04 |
| WO1998054089A1 (en) | 1998-12-03 |
| EP0984901A1 (en) | 2000-03-15 |
| BG101544A (en) | 1998-11-30 |
| US6428803B1 (en) | 2002-08-06 |
| ATE246146T1 (en) | 2003-08-15 |
| AU8434898A (en) | 1998-12-30 |
| CA2291677A1 (en) | 1998-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0984901B1 (en) | Hydroxylapatite gel | |
| DE2724972C2 (en) | ||
| DE68928816T2 (en) | Calcium phosphate mineral compositions and process for their preparation | |
| DE69326082T2 (en) | CALCIUM PHOSPHATE AS A HYDROXYAPATITE PRECURSOR AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| DE69812709T2 (en) | PROCESS FOR THE PRODUCTION OF APATITIC CERAMICS, IN PARTICULAR FOR BIOLOGICAL USE | |
| DE69702610T2 (en) | METHOD FOR PRODUCING HYDROXYLAPATITE COATINGS | |
| DE69000659T2 (en) | COMPOSITIONS FOR CALCIUM PHOSPHATE MINERALS MADE IN SITU. | |
| DE69804506T2 (en) | METHOD FOR PRODUCING HYDROXYAPATITE SUBSTITUTED WITH CARBONATE AND MAGNESIUM | |
| DE69322765T2 (en) | CARBONATED HYDROXYAPATITE COMPOSITIONS AND THEIR USE | |
| EP0230570B1 (en) | Porous hydroxy apatite material | |
| DE69228793T2 (en) | METHOD FOR PRODUCING AN IMPLANT COATED WITH HYDROXYLAPATITE | |
| DE60300666T2 (en) | Process for the preparation of porous calcium phosphate chips and granules from gelatine processing | |
| EP0193588B1 (en) | Material containing carbonate apatite and use of carbonate apatite for implants | |
| DE3750849T2 (en) | SOLID CALCIUM PHOSPHATE MATERIALS. | |
| DE69803398T2 (en) | HYDRAULIC SURGICAL CEMENT | |
| DE2652611B2 (en) | Ceramic material for implants and process for their manufacture | |
| DE4029969A1 (en) | METHOD FOR PRODUCING BONE PROSTHESES | |
| EP1153621A1 (en) | Biocements based on a mixture of TCP-PHA with improved compressive strength | |
| DE2606540A1 (en) | BIOLOGICALLY COMPATIBLE GLASS CERAMICS | |
| EP1121161A1 (en) | Composition for implantation in the human and animal body | |
| DE4124898A1 (en) | APETITE-CONTAINED TETRACALCIUM PHOSPHATE PARTICLES | |
| DE3872862T2 (en) | COMPOSITION FOR PRODUCING A HARDENABLE CALCIUM PHOSPHATE-LIKE MATERIAL AND METHOD FOR PRODUCING SUCH A MATERIAL. | |
| DE69127447T2 (en) | INNER MIXTURE OF GALCIUM AND PHOSPHATE SOURCES AS HYDROXYAPATITE PRECURSORS | |
| DE69005074T2 (en) | Biomaterial for filling bones or teeth and process for its production. | |
| EP0237043B1 (en) | Biocompatible sheet material containing calcium phosphate, and method for making it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19991116 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT CH CY DE DK ES FI FR GB GR IT LI NL SE |
|
| 17Q | First examination report despatched |
Effective date: 20000717 |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Designated state(s): AT CH CY DE DK ES FI FR GB GR IT LI NL SE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030730 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030730 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030730 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REF | Corresponds to: |
Ref document number: 59809162 Country of ref document: DE Date of ref document: 20030904 Kind code of ref document: P |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031030 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031030 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20040308 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040526 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040527 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040527 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 |
|
| ET | Fr: translation filed | ||
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2209166 Country of ref document: ES Kind code of ref document: T3 |
|
| 26N | No opposition filed |
Effective date: 20040504 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041201 |
|
| EUG | Se: european patent has lapsed | ||
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20041201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050526 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20040527 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20061024 Year of fee payment: 9 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20070526 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20071102 Year of fee payment: 10 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20080131 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070531 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060531 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20060927 Year of fee payment: 9 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081202 |